Literature DB >> 24221343

Increased Toll-like receptor 5 expression indicates esophageal columnar dysplasia.

Olli Helminen1, Heikki Huhta, Heikki Takala, Petri P Lehenkari, Juha Saarnio, Joonas H Kauppila, Tuomo J Karttunen.   

Abstract

Toll-like receptor 5 (TLR5) is an immune receptor, which recognizes bacterial flagellin. Increased expression has been reported in various premalignant and malignant lesions indicating a role in carcinogenesis. We assessed the expression of TLR5 in normal esophageal squamous epithelium, Barrett's esophagus with and without dysplasia, and in esophageal adenocarcinoma. Specimens with normal esophagus (n=93), gastric (n=75) or intestinal metaplasia (n=53) without dysplasia, and low-grade (n=56) or high-grade dysplasia (n=33) and esophageal adenocarcinoma (n=94) were studied. TLR5 immunohistochemical stainings were analyzed for the proportion of positive cells and the intensity of expression. In normal squamous epithelium, only the basal third showed TLR5 expression. In esophageal gastric or intestinal metaplasia, expression was present in majority of the cells but significantly weaker (p<0.001) than in dysplastic epithelium. In dysplasia, expression extended to the apical cytoplasm, contrasting basolateral expression in non-dysplastic columnar epithelium. Receiver operating characteristic curve analysis showed that moderate to high expression intensity of TLR5 indicates low-grade dysplasia with 86 % sensitivity and 83 % specificity. Carcinomas showed increased expression in comparison with non-dysplastic columnar epithelium, but there was no association with prognosis. Our results indicate that the esophageal columnar dysplasia is associated with clear increase of TLR5 expression and dissolution of regular polarized expression. TLR5 staining provides a possible biomarker for the recognition of low-grade dysplasia. In addition, the findings suggest a role for abnormal expression of TLR5 in the pathogenesis of esophageal adenocarcinoma and suggest importance of altered microbiome in the pathogenesis of complications of Barrett's esophagus.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24221343     DOI: 10.1007/s00428-013-1505-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  34 in total

1.  Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth.

Authors:  Zhenyu Cai; Amir Sanchez; Zhongcheng Shi; Tingting Zhang; Mingyao Liu; Dekai Zhang
Journal:  Cancer Res       Date:  2011-03-22       Impact factor: 12.701

Review 2.  Barrett esophagus: histology and pathology for the clinician.

Authors:  Robert D Odze
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07-07       Impact factor: 46.802

3.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

4.  Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia.

Authors:  Pedro Pimentel-Nunes; Luís Afonso; Paula Lopes; Roberto Roncon-Albuquerque; Nádia Gonçalves; Rui Henrique; Luís Moreira-Dias; Adelino F Leite-Moreira; Mário Dinis-Ribeiro
Journal:  Pathol Oncol Res       Date:  2011-04-01       Impact factor: 3.201

5.  Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5.

Authors:  Eun-Jung Song; Min-Jung Kang; Yong-Seok Kim; Sun-Moon Kim; Sang-Eok Lee; Chang-Hwan Kim; Dong-Jae Kim; Jong-Hwan Park
Journal:  Int J Mol Med       Date:  2011-03-23       Impact factor: 4.101

6.  Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated.

Authors:  Wouter L Curvers; Fiebo J ten Kate; Kausilia K Krishnadath; Mike Visser; Brenda Elzer; Lubertus C Baak; Clarisse Bohmer; Rosalie C Mallant-Hent; Arnout van Oijen; Anton H Naber; Pieter Scholten; Olivier R Busch; Harriët G T Blaauwgeers; Gerrit A Meijer; Jacques J G H M Bergman
Journal:  Am J Gastroenterol       Date:  2010-05-11       Impact factor: 10.864

7.  Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome.

Authors:  Liying Yang; Xiaohua Lu; Carlos W Nossa; Fritz Francois; Richard M Peek; Zhiheng Pei
Journal:  Gastroenterology       Date:  2009-04-23       Impact factor: 22.682

8.  Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer.

Authors:  Sang Hoon Rhee; Eunok Im; Charalabos Pothoulakis
Journal:  Gastroenterology       Date:  2008-04-23       Impact factor: 22.682

9.  Bacterial biota in the human distal esophagus.

Authors:  Zhiheng Pei; Edmund J Bini; Liying Yang; Meisheng Zhou; Fritz Francois; Martin J Blaser
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

10.  Increased expression of Toll-like receptor 5 during progression of cervical neoplasia.

Authors:  W Y Kim; J-W Lee; J-J Choi; C H Choi; T-J Kim; B-G Kim; S Y Song; D-S Bae
Journal:  Int J Gynecol Cancer       Date:  2007-06-22       Impact factor: 3.437

View more
  19 in total

1.  Nuclear localization of Toll-like receptor 5 in Barrett's esophagus and esophageal adenocarcinoma is associated with metastatic behavior.

Authors:  Olli Helminen; Heikki Huhta; Joni Leppänen; Joonas H Kauppila; Heikki Takala; Petri P Lehenkari; Juha Saarnio; Tuomo J Karttunen
Journal:  Virchows Arch       Date:  2016-07-09       Impact factor: 4.064

2.  Toll-like receptor 9 expression in the natural history of Barrett mucosa.

Authors:  Heikki Huhta; Olli Helminen; Joonas H Kauppila; Heikki Takala; Kalervo Metsikkö; Petri Lehenkari; Juha Saarnio; Tuomo Karttunen
Journal:  Virchows Arch       Date:  2015-04-03       Impact factor: 4.064

3.  High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.

Authors:  Joni Leppänen; Olli Helminen; Heikki Huhta; Joonas H Kauppila; Joel Isohookana; Kirsi-Maria Haapasaari; Petri Lehenkari; Juha Saarnio; Tuomo J Karttunen
Journal:  Virchows Arch       Date:  2017-02-12       Impact factor: 4.064

Review 4.  Microbiome, innate immunity, and esophageal adenocarcinoma.

Authors:  Jonathan Baghdadi; Noami Chaudhary; Zhiheng Pei; Liying Yang
Journal:  Clin Lab Med       Date:  2014-09-26       Impact factor: 1.935

5.  Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.

Authors:  Minna Nortunen; Heikki Huhta; Olli Helminen; Seppo Parkkila; Joonas H Kauppila; Tuomo J Karttunen; Juha Saarnio
Journal:  Virchows Arch       Date:  2018-07-31       Impact factor: 4.064

6.  Expression of toll-like receptors in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma--an in vivo and in vitro study.

Authors:  Lauri Jouhi; Neeta Datta; Suvi Renkonen; Timo Atula; Antti Mäkitie; Caj Haglund; Abdirisak Ahmed; Stina Syrjänen; Reidar Grénman; Eeva Auvinen; Sanna Lehtonen; Jaana Hagström
Journal:  Tumour Biol       Date:  2015-05-05

7.  Nucleic acid-sensing toll-like receptors 3, 7 and 8 in esophageal epithelium, barrett's esophagus, dysplasia and adenocarcinoma.

Authors:  Olli Helminen; Heikki Huhta; Petri P Lehenkari; Juha Saarnio; Tuomo J Karttunen; Joonas H Kauppila
Journal:  Oncoimmunology       Date:  2016-01-25       Impact factor: 8.110

8.  Association between Toll-like receptor 7 Gln11Leu single-nucleotide polymorphism and basal cell carcinoma.

Authors:  Irene Russo; Camilla Cona; Andrea Saponeri; Franco Bassetto; Vincenzo Baldo; Mauro Alaibac
Journal:  Biomed Rep       Date:  2016-02-15

Review 9.  Toll-like receptors in esophageal cancer.

Authors:  Joonas H Kauppila; Katri S Selander
Journal:  Front Immunol       Date:  2014-05-07       Impact factor: 7.561

10.  Immunohistochemical Analysis of Toll-Like Receptors, MyD88, and TRIF in Human Papillary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.

Authors:  Yasuhiro Nihon-Yanagi; Megumi Wakayama; Naobumi Tochigi; Fumi Saito; Hideaki Ogata; Kazutoshi Shibuya
Journal:  J Thyroid Res       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.